Keith Meister Sells 106,543 Shares of Illumina (NASDAQ:ILMN) Stock

Illumina, Inc. (NASDAQ:ILMN) Director Keith Meister sold 106,543 shares of the business’s stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $225.46, for a total transaction of $24,021,184.78. Following the transaction, the director directly owned 1,172,289 shares of the company’s stock, valued at approximately $264,304,277.94. This trade represents a 8.33% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Illumina Stock Performance

Shares of ILMN stock traded up $2.85 during trading hours on Thursday, reaching $227.69. The stock had a trading volume of 1,937,136 shares, compared to its average volume of 2,109,322. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. Illumina, Inc. has a twelve month low of $88.00 and a twelve month high of $231.81. The firm has a 50-day simple moving average of $192.98 and a 200-day simple moving average of $155.18. The firm has a market capitalization of $34.38 billion, a PE ratio of 42.48, a price-to-earnings-growth ratio of 3.16 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The firm had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. During the same period in the previous year, the business posted $1.19 EPS. Illumina’s revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, equities analysts forecast that Illumina, Inc. will post 5.36 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have recently commented on ILMN. Stifel Nicolaus raised their price target on Illumina from $155.00 to $225.00 and gave the company a “buy” rating in a report on Friday, July 31st. Guggenheim upped their price objective on shares of Illumina from $200.00 to $226.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Barclays increased their target price on shares of Illumina from $145.00 to $160.00 and gave the company an “underweight” rating in a research report on Friday, July 31st. Citigroup boosted their price target on shares of Illumina from $95.00 to $113.00 and gave the stock a “sell” rating in a research report on Monday, August 3rd. Finally, Daiwa Securities Group raised shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price target for the company in a research note on Thursday, May 14th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $188.40.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Fiduciary Financial Advisors acquired a new position in shares of Illumina in the 2nd quarter worth approximately $26,000. Keating Financial Advisory Services Inc. acquired a new stake in Illumina during the second quarter valued at approximately $32,000. Rakuten Securities Inc. bought a new stake in Illumina during the second quarter worth approximately $33,000. Elyxium Wealth LLC bought a new stake in Illumina during the fourth quarter worth approximately $25,000. Finally, TD Waterhouse Canada Inc. acquired a new position in Illumina in the fourth quarter worth approximately $26,000. Institutional investors own 89.42% of the company’s stock.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.